Telephone:
(925) 558-5040
en
-横版-原色.webp "Crystal Pharmatech Co., Ltd."){kind=logo}
A data-driven developability assessment strategy that guides compounds from lead optimization toward First-in-Human (FIH) studies with greater confidence and reduced development risk.
Drug development programs often encounter significant delays when physicochemical and developability risks are not evaluated early. Without a clear understanding of API properties and formulation behavior, programs can face unexpected challenges as they progress toward GLP toxicology studies and First-in-Human (FIH) trials.
Common obstacles include:
Uncertain Physicochemical Properties: Limited understanding of API form and formulation behavior can lead to incorrect development decisions.
Lack of Quantitative Comparison: Lead compounds often require systematic, head-to-head benchmarking to identify the most developable candidate.
Inconsistent Toxicology Exposure: Formulation guesswork can lead to variable exposure and delayed or failed toxicology studies.
To overcome these challenges, innovators need a data-driven developability assessment strategy that provides a comprehensive understanding of a compound’s potential for development.
Crystal Pharmatech's scientific experts bring decades of experience in developability assessment and early-stage CMC strategy. By integrating experimental data, in silico simulations, and industry benchmarking, we translate complex molecular information into clear development guidance.
This approach enables drug developers to:
Define clear next steps from lead candidate selection through formulation development and early clinical studies.
Minimize trial-and-error experimentation through strategic data-driven decision making.
Ensure that CMC considerations do not limit toxicology studies or Phase I clinical development while identifying potential developability risks early.
With as little as 500 mg of API and approximately four weeks, Crystal Pharmatech's developability assessment provides actionable insights to guide early development decisions.
Determine key physicochemical properties of your compound: Precise characterization of critical API attributes that influence formulation and development strategy.
Benchmark your molecule against established industry standards: Quantitative comparison of lead candidates to identify the most developable compound.
Define a clear path toward GLP toxicology and First-in-Human studies: A structured, step-by-step development strategy that supports successful clinical progression.
Before selecting a lead compound, conducting salt screening, or advancing to formulation development, it is critical to understand the physicochemical and biopharmaceutical properties of the molecule.
A comprehensive developability assessment provides insights that extend beyond individual experimental results. By combining API-sparing experimental technologies with advanced in silico modeling and data-driven analysis, developers can better predict in vivo performance and make more informed decisions earlier in small molecule drug development.
Subscribe to be the first to get the updates!